Pharmathen

Pharmathen company information, Employees & Contact Information

Explore related pages

Related company profiles:

Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of complex drug delivery technologies. Pharmathen is committed to its vision to improve people’s lives through innovation and access to affordable medicines. The company has one of the most extensive and advanced pipelines in the industry, with a focus on long acting injectables (LAI), sustained release and ophthalmic formulations. Pharmathen’s highly diversified portfolio consists of over 100 commercialized products, which are produced in its US FDA and EU-approved manufacturing facilities in Greece, serving 250 customers and accessed by patients in more than 90 countries worldwide. Pharmathen is constantly strengthening its portfolio with innovative technologies and Long-Acting Therapeutic Technologies (LATTs) and has developed three fully certified technological platforms to achieve this. As a result, Pharmathen can provide a wide range of therapies which aim to improve treatment compliance for patients and support product Life Cycle Management (LCM) opportunities for customers. Pharmathen maintains a strong presence in all major markets and collaborates with the most significant organizations in the global pharmaceutical market, supported by a broad partner network in more than 90 countries worldwide. The company ranks among the top 50 pharmaceutical research companies in Europe and is one of the largest private sector investors in research and development in Greece. Pharmathen proudly employs more than 1,600 people from over 28 different nationalities, with 54% of its total workforce and 66% of its Research Operations Team being female. The company's enduring success is attributed to a passion for creativity, strong ethics, and the dedication of its people, who share a commitment to the company's vision of making a difference in people’s lives.

Company Details

Employees
1.07K
Founded
-
Address
44, Kifissias Avenue, Marousi,attica 15125,greece
Phone
+31 (0) 20 799 5085
Email
in****@****hen.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Marousi, Attica
Looking for a particular Pharmathen employee's phone or email?

Pharmathen Questions

News

Patent case: Pharmathen Global B.V. vs. Novartis AG, Netherlands - Wolters Kluwer

Patent case: Pharmathen Global B.V. vs. Novartis AG, Netherlands Wolters Kluwer

Partners Group Said to Near Deal for BC’s Drugmaker Pharmathen - Private Equity Insights

Partners Group Said to Near Deal for BC’s Drugmaker Pharmathen Private Equity Insights

CNS link-up between Neuraxpharm and Pharmathen - The Pharma Letter

CNS link-up between Neuraxpharm and Pharmathen The Pharma Letter

Widely prescribed mental health drugs out of stock in French pharmacies - The Connexion

Widely prescribed mental health drugs out of stock in French pharmacies The Connexion

Partners Group to acquire Pharmathen from BC Partners for $1.9bn - Pharmaceutical Technology

Partners Group to acquire Pharmathen from BC Partners for $1.9bn Pharmaceutical Technology

Dutch court extends cross-border jurisdiction in Novartis and Pharmathen battle - JUVE Patent

Dutch court extends cross-border jurisdiction in Novartis and Pharmathen battle JUVE Patent

Sustained release specialist sold in $1.9B private equity deal, teeing up push into U.S. market - Fierce Pharma

Sustained release specialist sold in $1.9B private equity deal, teeing up push into U.S. market Fierce Pharma

Partners Group Agrees to Buy BC’s Drugmaker Pharmathen - Bloomberg.com

Partners Group Agrees to Buy BC’s Drugmaker Pharmathen Bloomberg.com

Pharmathen acquires local firm CBL Patras - eKathimerini.com

Pharmathen acquires local firm CBL Patras eKathimerini.com

Dutch court halts sale of Pharmathen cancer drug Okrodin in Europe - JUVE Patent

Dutch court halts sale of Pharmathen cancer drug Okrodin in Europe JUVE Patent

BC Partners sells Pharmathen for 1.6 bln euros - eKathimerini.com

BC Partners sells Pharmathen for 1.6 bln euros eKathimerini.com

Deal on medicine: Pharmathen acquires CBL Patras for €80 million - BusinessDaily

Deal on medicine: Pharmathen acquires CBL Patras for €80 million BusinessDaily

Pharmathen makes inroads in Australia - Neos Kosmos

Pharmathen makes inroads in Australia Neos Kosmos

BC Partners starts 1.5-bln-euro Pharmathen sale hiring Jefferies - eKathimerini.com

BC Partners starts 1.5-bln-euro Pharmathen sale hiring Jefferies eKathimerini.com

Pharmathen posts rise in drug profits - eKathimerini.com

Pharmathen posts rise in drug profits eKathimerini.com

Top Pharmathen Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant